Piramal Pharma has completed the acquisition of an additional 40.67 percent stake in Yapan Bio, increasing its ownership in the company from 33.33 percent to 74 percent. The transaction was completed for an aggregate cash consideration of approximately INR 76 crore.

Following the acquisition, Yapan Bio has ceased to be an associate company and has become a subsidiary of Piramal Pharma.

Yapan Bio, incorporated in 2019, is a CDMO specialising in process development, characterisation and phase 1/2 Good Manufacturing Practice (GMP) manufacturing services for vaccines and biologics.

The company reported revenue from operations of INR 26.91 crore in FY2024, INR 54.40 crore in FY2025 and INR 26.34 crore in FY2026, according to the regulatory disclosure.

The company said the acquisition will enable it to fully integrate Yapan Bio’s advanced large-molecule capabilities into its broader service offering, supporting the development and scaling of complex biologic therapies with greater efficiency.

The transaction follows the company’s earlier communication dated August 10, 2026, regarding the exercise of its call option to acquire the additional stake in Yapan Bio. The completion of the acquisition was disclosed to the stock exchanges on August 18, 2026, under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Regulations.